文献速递糖尿病

英国1型糖尿病患者中Dexcom G6实时持续葡萄糖监测与自我血糖监测的长期成本效益

Long-term Cost-Effectiveness of Dexcom G6 Real-time Continuous Glucose Monitoring Versus Self-Monitoring of Blood Glucose in Patients With Type 1 Diabetes in the U.K.
PubMed 文献 · Diabetes Care · 2020-07-09

基于IQVIA CORE糖尿病模型和DIAMOND试验数据,从英国国家医疗服务体系支付方视角进行终身分析。在基线HbA1c≥7.5%的患者中,G6实时持续葡萄糖监测较自我血糖监测增加1.49个质量调整生命年,增量成本效益比为每获得1个质量调整生命年9558英镑,低于每质量调整生命年20000英镑的支付意愿阈值,具有成本效益。

要点

  • 在基线HbA1c≥7.5%的1型糖尿病患者中,G6实时持续葡萄糖监测较自我血糖监测增加1.49个质量调整生命年。
  • G6实时持续葡萄糖监测的终身总成本较自我血糖监测高14234英镑,增量成本效益比为每质量调整生命年9558英镑。
  • 基于每质量调整生命年20000英镑的支付意愿阈值,G6实时持续葡萄糖监测在英国1型糖尿病患者中具有成本效益。

核心结论

  • 对于英国1型糖尿病患者,G6实时持续葡萄糖监测设备与临床结局的显著改善相关,且相对于自我血糖监测,基于每质量调整生命年20000英镑的支付意愿阈值,在患者终身时间范围内是一种具有成本效益的疾病管理选择。

研究设计与样本

  • 采用IQVIA CORE糖尿病模型进行长期健康经济学分析,临床输入数据来源于成人1型糖尿病患者的DIAMOND试验。
  • 模拟在基线HbA1c≥7.5%(58 mmol/mol)的总体人群和基线HbA1c≥8.5%(69 mmol/mol)的次要分析人群中分别进行。
  • 分析从英国国家医疗服务体系医疗支付方视角进行,时间范围为终身。

主要发现

  • 在总体人群中,G6实时持续葡萄糖监测较自我血糖监测平均增加1.49个质量调整生命年(平均[标准差]11.47[2.04]个质量调整生命年 vs 9.99[1.84]个质量调整生命年)。
  • G6实时持续葡萄糖监测的终身总平均(标准差)成本较自我血糖监测高14234英镑(102468[35681]英镑 vs 88234[39027]英镑),增量成本效益比为每获得1个质量调整生命年9558英镑。
  • 敏感性分析显示,结果对与减少低血糖恐惧和避免指尖采血相关的质量-of-life获益变化以及RT-CGM使用相关的HbA1c获益变化敏感。

关键数值与推荐

  • 增量成本效益比为每获得1个质量调整生命年9558英镑。
  • 支付意愿阈值为每质量调整生命年20000英镑。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: A long-term health economic analysis was performed to establish the cost-effectiveness of real-time continuous glucose monitoring (RT-CGM) (Dexcom G6) versus self-monitoring of blood glucose (SMBG) alone in U.K.-based patients with type 1 diabetes (T1D). RESEARCH DESIGN AND METHODS: The analysis used the IQVIA CORE Diabetes Model. Clinical input data were sourced from the DIAMOND trial in adults with T1D. Simulations were performed separately in the overall population of patients with baseline HbA1c ≥7.5% (58 mmol/mol), and a secondary analysis was performed in patients with baseline HbA1c ≥8.5% (69 mmol/mol). The analysis was performed from the National Health Service health care payer perspective over a lifetime time horizon. RESULTS: In the overall population, G6 RT-CGM was associated with a mean incremental gain in quality-adjusted life expectancy of 1.49 quality-adjusted life years (QALYs) versus SMBG (mean [SD] 11.47 [2.04] QALYs versus 9.99 [1.84] QALYs). Total mean (SD) lifetime costs were also pounds sterling (GBP) 14,234 higher with RT-CGM (GBP 102,468 [35,681] versus GBP 88,234 [39,027]) resulting in an incremental cost-effectiveness ratio of GBP 9,558 per QALY gained. Sensitivity analyses revealed that the findings were sensitive to changes in the quality-of-life benefit associated with reduced fear of hypoglycemia and avoidance of fingerstick testing as well as the HbA1c benefit associated with RT-CGM use. CONCLUSIONS: For U.K.-based T1D patients, the G6 RT-CGM device is associated with significant improvements in clinical outcomes and, over patient lifetimes, is a cost-effective disease management option relative to SMBG on the basis of a willingness-to-pay threshold of GBP 20,000 per QALY gained.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Roze S, Isitt J, Smith-Palmer J, et al. Long-term Cost-Effectiveness of Dexcom G6 Real-time Continuous Glucose Monitoring Versus Self-Monitoring of Blood Glucose in Patients With Type 1 Diabetes in the U.K. Diabetes Care. 2020. PMID: 32647050. doi:10.2337/dc19-2213

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。